Codexis, Inc. develops enzyme-based solutions for therapeutics manufacturing, using its CodeEvolver technology to discover and improve high-performance enzymes. Company news commonly covers financial results, guidance, cash-runway commentary, and business updates tied to small molecule pharmaceutical biocatalysis, nucleic acid synthesis, and the ECO Synthesis manufacturing platform for enzymatic RNAi and siRNA production.
Recurring developments include partner and evaluation agreements, technology-transfer activity, quality-system and manufacturing-suite updates, conference data on ECO Synthesis capabilities such as phosphorothioate stereochemistry and ligation efficiency, and portfolio updates for enzymes used in branded pharmaceutical products.
Codexis appoints Stefan Lutz, Ph.D. as Senior Vice President of Research, and Karl A. Schoene, Ph.D. as Senior Vice President of Development & Operations, effective immediately. These new roles are pivotal for the growth of Codexis' Performance Enzymes and Novel Biotherapeutics segments. Lutz brings extensive expertise in protein engineering, while Schoene has a proven track record in commercializing specialty chemical products. Their leadership is expected to enhance Codexis' innovative capabilities and operational efficiency, positioning the company for future expansion.
Summary not available.